Dr Reddy's launches generic Parkinson's disease tablets in US

Dr Reddy's Laboratories today said it has launched its generic Ropinirole Hydrochloride XR tablets used for treating Parkinson’s disease in the American market after receiving approval from the US health regulator.

The company has launched Ropinirole Hydrochloride XR (extended-release) tablets in the strengths of 2 mg, 4 mg, 6 mg, 8mg, and 12 mg in the US market, Dr Reddy's said in a statement.

The launch follows approval by the United States Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA).

The tablets are bio equivalent generic version of GlaxoSmithKline's Requip XL tablets, it added.

Quoting IMS health, the company said that the Requip XL brand had sales of approximately $58 million in the American market for the twelve months ending March 2012.

The Hyderabad based firm's Ropinirole Hydrochloride XR (extended-release) tablets in the strengths of 2 mg, 4 mg and 6 mg are available in 30 and 90 count bottle sizes while 8 mg and 12 mg strengths are available in 30 count bottle sizes.

Scrips of Dr Reddy's Laboratories were today trading at Rs 1,618.80 per scrip in the afternoon trade on BSE, up 0.25% from its previous close.